SMAD2 and breast carcinoma: In ovarian cancer cells, Activin-A treatment promotes EMT via canonical SMAD2/3 signaling together with SMAD4 (57), whereas in colon and breast cancer cells, it has been reported to promote EMT and cell migration or invasiveness independently of SMAD4 (7, 58).